Zacks Research Upgrades Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) to “Hold”

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Several other analysts also recently weighed in on LKFT. Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Royal Bank Of Canada upped their target price on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 24th. Finally, UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Lakefront Biotherapeutics American Depositary Shares stock opened at $28.27 on Monday. The business’s 50-day simple moving average is $28.27 and its two-hundred day simple moving average is $31.19. The company has a market cap of $1.86 billion, a PE ratio of -20.05 and a beta of 0.26. Lakefront Biotherapeutics American Depositary Shares has a fifty-two week low of $26.42 and a fifty-two week high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion for the quarter. As a group, analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds have recently bought and sold shares of the business. Madison Avenue Partners LP boosted its position in Lakefront Biotherapeutics American Depositary Shares by 0.8% during the fourth quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after purchasing an additional 17,394 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2,490.1% during the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock valued at $49,083,000 after acquiring an additional 1,362,229 shares during the last quarter. UBS Group AG raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% during the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock valued at $11,427,000 after acquiring an additional 196,445 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% during the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after acquiring an additional 186,452 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after acquiring an additional 115,946 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.